Invitation to webcast about UPM’s growth and innovation in 1-03-2023, 15:13

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

The Metals Company Announces Conference and Event Schedule for Q1 2023 27-01-2023, 02:36